X

Trial Profile

Randomized phase II/III study of risedronate [risedronic acid] in combination with docetaxel versus docetaxel alone in patients with hormone refractory prostate cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 08 Nov 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risedronic acid (Primary) ; Docetaxel
Indications Bone metastases; Prostate cancer
Focus Therapeutic Use
Acronyms NePro

Most Recent Events

15 Aug 2009 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
29 Jun 2009 New source identified and integrated (Netherlands Trial Register; NTR469).
01 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com